Department of Internal Medicine II, Division of Angiology, Medical University Vienna, Vienna, Austria.
Atherosclerosis. 2011 Jul;217(1):240-8. doi: 10.1016/j.atherosclerosis.2011.03.018. Epub 2011 Apr 8.
Supervised exercise training (SET) is recommended as initial treatment to improve walking capacity in peripheral arterial disease (PAD) patients with intermittent claudication. Various mechanisms by which SET yields beneficial effects are postulated, however data regarding its influence on angiogenesis are scarce. Thus, we designed a prospective randomized controlled trial to study the impact of SET on markers of angiogenesis and endothelial function in PAD.
Forty PAD patients were randomized to SET on top of best medical treatment (SET+BMT) for 6 months versus best medical treatment (BMT) only. Endothelial progenitor cells (EPC) were assessed by whole-blood flow cytometry (co-expression of CD34+ CD133+ KDR+) and cell culture assays (endothelial cell-colony forming units, circulating angiogenic cells, migration assay) at baseline, 3, 6 and 12-months after inclusion. Changes of plasma levels of asymmetric dimethylarginine (ADMA), vascular endothelial growth factor (VEGF), stromal cell-derived factor-1 (SDF-1) and maximum walking distance were determined.
EPC - measured by flow cytometric and cell culture techniques - increased significantly upon training paralleled by a significant decrease of ADMA when compared to the BMT group (p<0.05). Six months after training cessation, the beneficial effect of SET on EPC diminished, but maximum walking distance was significantly improved compared to baseline and controls (p<0.05). No significant changes were observed for VEGF and SDF-1 plasma levels in time course.
SET increases circulating EPC counts and decreases ADMA levels reflecting enhanced angiogenesis and improved endothelial function, which might contribute to cardiovascular risk reduction.
有间歇性跛行的周围动脉疾病(PAD)患者,推荐监督运动训练(SET)作为改善步行能力的初始治疗。SET 产生有益效果的各种机制被推测,但关于其对血管生成影响的数据却很少。因此,我们设计了一项前瞻性随机对照试验,以研究 SET 对 PAD 患者血管生成和内皮功能标志物的影响。
40 名 PAD 患者随机分为 SET 加最佳药物治疗(SET+BMT)组和仅最佳药物治疗(BMT)组,共 6 个月。基线、3、6 和 12 个月时,通过全血流式细胞术(CD34+CD133+KDR+共表达)和细胞培养测定(内皮细胞集落形成单位、循环血管生成细胞、迁移测定)评估内皮祖细胞(EPC)。测定血浆不对称二甲基精氨酸(ADMA)、血管内皮生长因子(VEGF)、基质细胞衍生因子-1(SDF-1)和最大步行距离的变化。
通过流式细胞术和细胞培养技术测量的 EPC 在训练时显著增加,与 BMT 组相比,ADMA 显著下降(p<0.05)。停止训练 6 个月后,SET 对 EPC 的有益作用减弱,但与基线和对照组相比,最大步行距离显著改善(p<0.05)。VEGF 和 SDF-1 血浆水平在时间过程中没有观察到显著变化。
SET 增加循环 EPC 计数并降低 ADMA 水平,反映出血管生成增强和内皮功能改善,这可能有助于降低心血管风险。